BRPI1006104A2 - gene que codifica glucoquinase humana mutante, glucoquinase humana mutante, vetor recombinante, hospedeiro, composicao farmaceutica, uso de um gene, de uma glucoquinase humana mutante, de um vetor recombinante, de um hospedeiro e de uma composição farmacêutica - Google Patents
gene que codifica glucoquinase humana mutante, glucoquinase humana mutante, vetor recombinante, hospedeiro, composicao farmaceutica, uso de um gene, de uma glucoquinase humana mutante, de um vetor recombinante, de um hospedeiro e de uma composição farmacêuticaInfo
- Publication number
- BRPI1006104A2 BRPI1006104A2 BRPI1006104A BRPI1006104A BRPI1006104A2 BR PI1006104 A2 BRPI1006104 A2 BR PI1006104A2 BR PI1006104 A BRPI1006104 A BR PI1006104A BR PI1006104 A BRPI1006104 A BR PI1006104A BR PI1006104 A2 BRPI1006104 A2 BR PI1006104A2
- Authority
- BR
- Brazil
- Prior art keywords
- mutant human
- human glucokinase
- host
- pharmaceutical composition
- recombinant vector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01002—Glucokinase (2.7.1.2)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910000087 | 2009-01-07 | ||
| CN200910000087.1 | 2009-01-07 | ||
| PCT/CN2010/070038 WO2010078842A1 (zh) | 2009-01-07 | 2010-01-06 | 人葡萄糖激酶突变体编码基因、其编码的酶、重组载体及宿主、其药物组合物、应用以及预防和治疗疾病的方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI1006104A2 true BRPI1006104A2 (pt) | 2016-02-16 |
| BRPI1006104B1 BRPI1006104B1 (pt) | 2021-04-20 |
| BRPI1006104B8 BRPI1006104B8 (pt) | 2021-05-25 |
Family
ID=42316263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1006104A BRPI1006104B8 (pt) | 2009-01-07 | 2010-01-06 | gene isolado que codifica glucoquinase humana, vetor recombinante, hospedeiro, e, composição farmacêutica |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9029142B2 (pt) |
| EP (1) | EP2388317B1 (pt) |
| JP (1) | JP5721637B2 (pt) |
| KR (1) | KR101300540B1 (pt) |
| CN (1) | CN102272296B (pt) |
| AP (1) | AP3277A (pt) |
| AU (1) | AU2010204379B2 (pt) |
| BR (1) | BRPI1006104B8 (pt) |
| CA (1) | CA2749180C (pt) |
| DK (1) | DK2388317T3 (pt) |
| EA (1) | EA024878B1 (pt) |
| ES (1) | ES2649021T3 (pt) |
| HU (1) | HUE035110T2 (pt) |
| IL (1) | IL213750A (pt) |
| MA (1) | MA33034B1 (pt) |
| MX (1) | MX2011007263A (pt) |
| NZ (1) | NZ593893A (pt) |
| PT (1) | PT2388317T (pt) |
| SG (1) | SG172851A1 (pt) |
| WO (1) | WO2010078842A1 (pt) |
| ZA (1) | ZA201105209B (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201401054YA (en) | 2008-12-29 | 2014-07-30 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Peptides and compositions for prevention of cell adhesion and methods of using same |
| BRPI1006104B8 (pt) | 2009-01-07 | 2021-05-25 | Huang Haidong | gene isolado que codifica glucoquinase humana, vetor recombinante, hospedeiro, e, composição farmacêutica |
| WO2013117776A1 (es) * | 2012-02-08 | 2013-08-15 | Fundación Pública Andaluza Progreso Y Salud | Enzimas glucocinasas con actividad aumentada y su uso en el tratamiento y/o prevención de la diabetes mellitus |
| US9171343B1 (en) | 2012-09-11 | 2015-10-27 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
| US9897565B1 (en) | 2012-09-11 | 2018-02-20 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
| US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
| US9233204B2 (en) | 2014-01-31 | 2016-01-12 | Aseko, Inc. | Insulin management |
| JP6989262B2 (ja) | 2014-10-27 | 2022-01-05 | アセコー インコーポレイテッド | 皮下外来患者管理 |
| US11081226B2 (en) | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
| CA2993275C (en) | 2015-08-20 | 2022-06-21 | Aseko, Inc. | Diabetes management therapy advisor |
| CN110564777B (zh) * | 2019-09-23 | 2021-09-10 | 北京希诺谷生物科技有限公司 | 糖尿病疾病模型犬的建立方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0988388A2 (en) * | 1997-07-24 | 2000-03-29 | Valentis Inc. | Ghrh expression system and methods of use |
| US6689600B1 (en) * | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| ES2170720B1 (es) * | 2000-12-20 | 2003-12-16 | Univ Barcelona Autonoma | Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus. |
| US20070219346A1 (en) * | 2002-04-22 | 2007-09-20 | Mcgill University | Glucose sensor and uses thereof |
| WO2005052132A2 (en) * | 2003-11-24 | 2005-06-09 | Exelixis, Inc | Mbms as modifiers of branching morphogenesis and methods of use |
| GB0423173D0 (en) * | 2004-10-19 | 2004-11-24 | Univ Newcastle | Treatment of diabetes |
| KR20080036015A (ko) * | 2005-06-01 | 2008-04-24 | 주식회사 바이오텍 아이 | 글루코오스 유도성 인슐린 발현 및 당뇨병 치료 방법 |
| WO2009021276A1 (en) * | 2007-08-10 | 2009-02-19 | University Of Technology, Sydney | Cells genetically modified to comprise pancreatic islet glucokinase and uses thereof |
| BRPI1006104B8 (pt) | 2009-01-07 | 2021-05-25 | Huang Haidong | gene isolado que codifica glucoquinase humana, vetor recombinante, hospedeiro, e, composição farmacêutica |
-
2010
- 2010-01-06 BR BRPI1006104A patent/BRPI1006104B8/pt not_active IP Right Cessation
- 2010-01-06 ES ES10729101.5T patent/ES2649021T3/es active Active
- 2010-01-06 CA CA2749180A patent/CA2749180C/en active Active
- 2010-01-06 EP EP10729101.5A patent/EP2388317B1/en active Active
- 2010-01-06 KR KR20117017931A patent/KR101300540B1/ko active Active
- 2010-01-06 WO PCT/CN2010/070038 patent/WO2010078842A1/zh not_active Ceased
- 2010-01-06 HU HUE10729101A patent/HUE035110T2/en unknown
- 2010-01-06 PT PT107291015T patent/PT2388317T/pt unknown
- 2010-01-06 EA EA201170917A patent/EA024878B1/ru unknown
- 2010-01-06 SG SG2011048972A patent/SG172851A1/en unknown
- 2010-01-06 NZ NZ59389310A patent/NZ593893A/xx not_active IP Right Cessation
- 2010-01-06 DK DK10729101.5T patent/DK2388317T3/da active
- 2010-01-06 AU AU2010204379A patent/AU2010204379B2/en active Active
- 2010-01-06 CN CN2010800041374A patent/CN102272296B/zh active Active - Reinstated
- 2010-01-06 MA MA34075A patent/MA33034B1/fr unknown
- 2010-01-06 JP JP2011544778A patent/JP5721637B2/ja not_active Expired - Fee Related
- 2010-01-06 MX MX2011007263A patent/MX2011007263A/es active IP Right Grant
- 2010-01-06 AP AP2011005814A patent/AP3277A/xx active
-
2011
- 2011-06-23 IL IL213750A patent/IL213750A/en active IP Right Grant
- 2011-07-07 US US13/178,058 patent/US9029142B2/en active Active
- 2011-07-14 ZA ZA2011/05209A patent/ZA201105209B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010204379B2 (en) | 2014-02-13 |
| CN102272296A (zh) | 2011-12-07 |
| ES2649021T3 (es) | 2018-01-09 |
| EA201170917A1 (ru) | 2011-12-30 |
| HUE035110T2 (en) | 2018-05-02 |
| EP2388317A1 (en) | 2011-11-23 |
| US9029142B2 (en) | 2015-05-12 |
| WO2010078842A1 (zh) | 2010-07-15 |
| CA2749180C (en) | 2017-03-21 |
| EP2388317B1 (en) | 2017-08-30 |
| KR101300540B1 (ko) | 2013-09-02 |
| BRPI1006104B8 (pt) | 2021-05-25 |
| AP3277A (en) | 2015-05-31 |
| NZ593893A (en) | 2013-02-22 |
| DK2388317T3 (da) | 2017-11-27 |
| MA33034B1 (fr) | 2012-02-01 |
| CN102272296B (zh) | 2012-10-24 |
| JP2012514463A (ja) | 2012-06-28 |
| JP5721637B2 (ja) | 2015-05-20 |
| AP2011005814A0 (en) | 2011-08-31 |
| CA2749180A1 (en) | 2010-07-15 |
| KR20110099057A (ko) | 2011-09-05 |
| IL213750A (en) | 2015-11-30 |
| BRPI1006104B1 (pt) | 2021-04-20 |
| ZA201105209B (en) | 2012-09-26 |
| SG172851A1 (en) | 2011-08-29 |
| PT2388317T (pt) | 2017-11-27 |
| EA024878B1 (ru) | 2016-10-31 |
| MX2011007263A (es) | 2011-10-06 |
| US20110286984A1 (en) | 2011-11-24 |
| IL213750A0 (en) | 2011-07-31 |
| AU2010204379A1 (en) | 2011-07-28 |
| EP2388317A4 (en) | 2012-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190137T1 (hr) | Stabilne formulacije polipeptida i njihova uporaba | |
| BRPI1005931A2 (pt) | associação de compostos, uso de uma associação, produto em forma de kit, uso de um produto e composição farmacêutica | |
| BRPI0917315A2 (pt) | anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica | |
| BRPI1014316A2 (pt) | composição, e, uso de uma composição | |
| IL214822A0 (en) | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | |
| ZA201200239B (en) | Derivative of glp-1 analogue or its pharmaceutical salts and their use | |
| BR112013015816A2 (pt) | construção de dna para imunomodulação, composição farmacêutica, vacina e uso de uma construção de dna | |
| BR112013001571A2 (pt) | composto, composição farmacêutica, uso e método de prevenção ou tratamento de uma condição associada com a função do receptor gpr40 | |
| BR112012003842A2 (pt) | composição farmacêutica, método de formulação e uso da mesma | |
| BRPI0917001A2 (pt) | composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica | |
| BRPI1006953A2 (pt) | composição farmacêutica, e, uso de uma composição | |
| BRPI1008039A2 (pt) | composto, mistura, composição farmacêutica, e, uso de um coposto, de uma mistura ou de uma composição farmacêutica | |
| BRPI0816330A2 (pt) | Composição de polipeptídeo, método para produzir composição de polipeptídeo, construção de polipeptídeo, método para produzir uma construção de polipeptídeo, construção de ácido nucleico, medicamento ou composição de vacina, método para produzir um medicamento ou composição de vacina, e uso da composição de polipeptídeo, de uma construção de polipeptídeo, de uma construção de ácido nucléico ou de um medicamento ou de composição de vacina | |
| BR112013011152A2 (pt) | proteína beta-glucocerebrosidase recombinante variante, composição e uso da proteína betaglucocerebrosidase recombinante variante | |
| BR112013030396A2 (pt) | polipeptídeo, polinucleotídeo, vetor, célula hospedeira, composição imunogênica, vacina, e, uso de uma composição imunogênica ou de uma vacina | |
| PT2173868E (pt) | Preparação recombinante de porções de bromelaína seleccionadas | |
| HUE050793T2 (hu) | Rekombináns HCG-t tartalmazó gyógyászati készítmény | |
| BRPI1008887A2 (pt) | peptídeos de foxm1 e vacinas contendo os mesmo | |
| BRPI1006666A2 (pt) | " composição farmacêutica e uso de uma composição farmacêutica" | |
| DK2388317T3 (da) | Gen, som koder for en human glucokinasemutant, og anvendelser deraf til behandling eller forebyggelse af sygdom | |
| IL219155A0 (en) | Pharmaceutical formulations of nitrite and uses thereof | |
| BR112013015819A2 (pt) | construção de dna, composição farmacêutica e uso de uma construção de dna | |
| ZA201204619B (en) | Pharmaceutical composition comprising vitamin d analogue and cosolventsurfactant mixture | |
| BR112012016736A2 (pt) | composição , formulação farmacêutica e uso da composição" | |
| BRPI0913297A2 (pt) | composição, farmacêutica, uso de uma composição, e, kit terapêutico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/01/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/01/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B15V | Prolongation of time limit allowed | ||
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 16A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2861 DE 04-11-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |